SCHEMBL29414776

SCHEMBL29414776

Cc1ccc(S(=O)(=O)n2cc(C(=O)O)c3ccccc32)cc1

nearest known ligand 0.78

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ AKR1C3 P42330 1/20 0.78
▸ AKR1C1 Q04828 1/20 0.78
▸ LMNA P02545 1/20 0.68
▸ SMN1; SMN2 Q16637 1/20 0.68
▸ ALOX5 P09917 8/20 0.67
▸ PTGS2 P35354 1/20 0.67
▸ L3MBTL1 Q9Y468 1/20 0.65
▸ PLK1 P53350 1/20 0.64
▸ MEN1 O00255 1/20 0.64
▸ KMT2A Q03164 1/20 0.64
▸ KDM4E B2RXH2 1/20 0.63
▸ UBE2N P61088 1/20 0.63
▸ HTR6 P50406 3/20 0.57
▸ FABP4 P15090 1/20 0.56
▸ TNF P01375 1/20 0.55
▸ ALK Q9UM73 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12748306 1.00 AKR1C3 (0.78) AKR1C3AKR1C1LMNASMN1; SMN2ALOX5
SCHEMBL13302218 0.90 ALOX5 (0.68) AKR1C3AKR1C1LMNASMN1; SMN2ALOX5
SCHEMBL948989 0.90 AKR1C3 (0.83) AKR1C3AKR1C1LMNASMN1; SMN2ALOX5
SCHEMBL12748630 0.89 AKR1C3 (0.78) AKR1C3AKR1C1LMNASMN1; SMN2ALOX5
SCHEMBL949348 0.89 LMNA (0.82) AKR1C3AKR1C1LMNASMN1; SMN2ALOX5
SCHEMBL30689046 0.88 ALOX5 (0.65) AKR1C3AKR1C1LMNASMN1; SMN2ALOX5
SCHEMBL22638205 0.88 ALOX5 (0.65) AKR1C3AKR1C1LMNASMN1; SMN2ALOX5
SCHEMBL1466532 0.87 AKR1C3 (1.00) AKR1C3AKR1C1LMNASMN1; SMN2ALOX5
SCHEMBL7828918 0.87 ALOX5 (0.62) AKR1C3AKR1C1LMNASMN1; SMN2ALOX5
SCHEMBL12748623 0.86 AKR1C3 (0.78) AKR1C3AKR1C1LMNASMN1; SMN2ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3965884-A1 MODULATORS OF THR-BETA AND METHODS OF USE THEREOF Aligos Therapeutics, Inc. (US) 2022-03-16 — — EP disclosed
Send feedback